Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Travel credit cards come with various features that can enhance your travel experience. Learn essential insights to maximize your benefits.
25,344 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A day of mixed signals, with Nvidia’s surge fading and tech shares pulling the Nasdaq and S&P 500 lower. Here’s what ...
Meta is dialing back its grand metaverse bet. This pivot could reshape the company’s profits and the stock’s long-run...
Builders are flocking to fast-growing regions. This guide explains which markets are rising, why lenders support them...
A hypothetical SpaceX IPO could ride a powerful tailwind if a Google cloud deal brings $30 billion in AI compute reve...
Coke trading steepest premium to Pepsi in years has market watchers asking what’s next. This article breaks down the ...
Concentra's Q4 2025 results shed light on its growth engine and profitability. This article breaks down the numbers, ...
March brought a mix of regulatory headlines and upbeat AI-related gains. This article breaks down what happened in th...
When a heavyweight like SPGI outperforms in a quiet market, it often signals more than a single stock move. This piec...
ASML Holding stock popped today as investors weighed AI-driven demand, backlog strength, and a brighter outlook for c...
Box and DocuSign sit at different corners of the SaaS world. This analysis shows how quarterly revenue patterns illum...
Paramount’s move to revive G.I. Joe with a controversial hire is more than a movie decision—it’s a case study in risk...